The Li–Fraumeni syndrome and the role of TP53 mutations in predisposition to cancer

Genetic Predisposition to Cancer, Second Edition

Volumn , Issue , 2003, Pages 141-154

  Birch, Jillian M ^a  

^a ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 28444494543     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (155)

1. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969; 71:747–752.
2. Li FP, Fraumeni JF Jr. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 1969; 43:1365–1373.
3. Bottomley RH, Trainer AL, Condit PT. Chromosome studies in a ‘cancer family’. Cancer 1971; 28:519–528.
4. Lynch HT, Krush AJ, Harlan WL, et al. Association of soft tissue sarcoma, leukemia and brain tumors in families affected with breast cancer. Am Surg 1973; 39:199–206.
5. Blattner WA, McGuire DB, Mulvihill JJ, et al. Genealogy of cancer in a family. JAMA 1979; 241, 259–261.
6. Pearson ADJ, Craft AW, Ratcliffe JM, et al. Two families with the Li–Fraumeni cancer family syndrome. J Med Genet 1982; 19:362–365.
7. Li FP, Fraumeni JF Jr. Prospective study of a family cancer syndrome. JAMA 1982; 247:2692–2694.
8. Birch JM, Hartley AL, Marsden HB, et al. Excess risk of breast cancer in the mothers of children with soft tissue sarcomas. Br J Cancer 1984; 49, 325–331.
9. Birch JM, Hartley AL, Blair V, et al. Cancer in the families of children with soft tissue sarcoma. Cancer 1990; 66:2239–2248.
10. Birch JM, Hartley AL, Blair V, et al. Identification of factors associated with high breast cancer risk in the mothers of children with soft tissue sarcoma. J Clin Oncol 1990; 8:583–590.
11. Strong, LC, Stine M, Norsted TL. Cancer in survivors of childhood soft tissue sarcoma and their relatives. J Natl Cancer Inst 1987; 79:1213–1220.
12. Williams WR, Strong LC. Genetic epidemiology of soft tissue sarcomas in children. In: Muller H, Weber W (eds) Familial cancer. First International Research Conference on Familial Cancer, Basel, 1985. Basel: Karger, 1995:151–153.
13. Lustbader ED, Williams WR, Bondy ML. et al. Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. Am J Hum Genet 1992; 51:344–356.
14. Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988; 48:5358–5362.
15. Hartley AL, Birch JM, Marsden HB, et al. Malignant melanoma in families of children with osteosarcoma, chondrosarcoma and adrenal cortical carcinoma. J Med Genet 1987; 24, 664–668.
16. Hartley AL, Birch JM, Kelsey AM, et al. Are germ cell tumours part of the Li–Fraumeni Cancer Family Syndrome? Cancer Genet Cytogenet 1989; 42:221–226.
17. Hartley AL, Birch JM, Tricker K, et al. Wilms tumour in the Li Fraumeni cancer family syndrome. Cancer Genet Cytogenet 1993; 67:133–135.
18. Malkin D, Li FP, Strong LC, et al. Germline p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 1990; 250:1233–1238.
19. Lavigueur A, Maltby V, Mock D, et al. High incidence of lung, bone and lymphoid tumors in transgenic mice over-expressing mutant alleles of the p53 oncogene. Mol Cell Biol 1989; 9:3982–3991.
20. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000; 77:81–137.
21. Malkin D, Friend SH. Correction: a Li–Fraumeni syndrome p53 mutation. Science 1993; 259:878.
22. Srivastava S, Zou Z, Pirollo K, et al. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome. Nature 1990; 348:747–749.
23. Vogelstein B. A deadly inheritance. Nature 1990; 348:681–682.
24. Auer H, Warncke K, Nowak D, et al. Variations of p53 in cultured fibroblasts of patients with lung cancer who have a presumed genetic predisposition. Am J Clin Oncol 1999; 22:278–282.
25. Ayan I, Luca JW, Jaffe N, et al. De novo germline mutations of the p53 gene in young children with sarcomas. Oncology Rep 1997; 4:679–683.
26. Bang Y-J, Kang S-H, Kim T-Y, et al. The first documentation of Li–Fraumeni syndrome in Korea. J Korean Med Sci 1995; 10:205–210.
27. Bardeesy N, Falkoff D, Petruzzi M-J, et al. Anaplastic Wilms tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nature Genet 1994; 7:91–97.
28. Birch JM, Hartley AL, Tricker KJ, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li–Fraumeni families. Cancer Res 1994; 54:1298–1304.
29. Blau O, Avigad S, Stark B, et al. Exon 5 mutations in the p53 gene in relapsed childhood acute lymphoblastic leukemia. Leuk Res 1997; 21:721–729.
30. Børresen A-L, Andersen TI, Garber J. Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 1992; 52:3234–3236.
31. Bot FJ, Sleddens HFBM, Dinjens WNM. Molecular assessment of clonality leads to the identification of a new germ line TP53 mutation associated with malignant cystosarcoma phyllodes and soft tissue sarcoma. Diagnos Mol Path 1998; 7:295–301.
32. Brugiéres L, Gardes M, Moutou C, et al. Screening for germ line p53 mutations in children with malignant tumors and a family history of cancer. Cancer Res 1993; 53:452–455.
33. Camplejohn RS, Sodha N, Gilchrist R, et al. The value of rapid functional assays of germline p53 status in LFS and LFL families. Br J Cancer 2000; 82:1145–1148.
34. Chen P, Iavarone A, Fick J, et al. Constitutional p53 mutations associated with brain tumors in young adults. Cancer Genet Cytogenet 1995; 82:106–115.
35. Chompret, A, Brugiéres L, Ronsin M, et al. p53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 2000; 82:1932–1937.
36. Chung R, Whaley J, Kley N, et al. TP53 gene mutations and 17p deletions in human astrocytomas. Genes Chromosomes Cancer 1991; 3:323–331.
37. Cornelis RS, van Vliet M, van de Vijver MJ, et al. Three germline mutations in the TP53 gene. Hum Mutat 1997; 9:157–163.
38. Diller L, Sexsmith E, Gottlieb A, et al. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest 1995; 95:1606–1611.
39. Dockhorn-Dworniczak B, Wolff J, Poremba C, et al. A new germline TP53 gene mutation in a family with Li–Fraumeni syndrome. Eur J Cancer 1996; 32A:1359–1365.
40. Eeles RA, Warren W, Knee G, et al. Constitutional mutation in exon 8 of the p53 gene in a patient with multiple primary tumours: molecular and immunohistochemical findings. Oncogene 1993; 8:269–1276.
41. Felix CA, Hosler MR, Provisor D, et al. The p53 gene in pediatric therapy-related leukemia and myelodysplasia. Blood 1996; 87:4376–4381.
42. Felix CA, Megonigal MD, Chervinsky DS, et al. Association of germline p53 mutation with MLL segmental jumping translocation in treatment related leukemia. Blood 1998; 91:4451–4456.
43. Felix CA, Nau MM, Takahashi T, et al. Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. J Clin Invest 1992; 89:640–647.
44. Felix CA, Slavc I, Dunn M, et al. p53 gene mutations in pediatric brain tumors. Med Pediat Oncol 1995; 25: 431–436.
45. Felix CA, Strauss EA, D’Amico D, et al. A novel germline p53 splicing mutation in a pediatric patient with a second malignant neoplasm. Oncogene 1993; 8:1203–1210.
46. Flaman JM, Frebourg T, Moreau V, et al. A simple p53 functional assay for screening cell lines, blood and tumors. Proc Natl Acad Sci 1995; 92:3963–3967.
47. Frebourg T, Barbier N, Yan Y-X, et al. Germ-line p53 mutations in 15 families with Li–Fraumeni syndrome. Am J Hum Genet 1995; 56:608–615.
48. Gallo O, Sardi I, Pepe G, et al. Multiple primary tumors of the upper aerodigestive tract: is there a role for constitutional mutations in the p53 gene? Int J Cancer 1999; 82:180–186.
49. Garcia AG, Barros F, Bouzas ML, et al. Li–Fraumeni syndrome and osteosarcoma of the maxilla. J Oral Maxillofac Surg 1998; 56:1106–1109.
50. Giunta C, Youil R, Venter D, et al. Rapid diagnosis of germline p53 mutation using the enzyme mismatch cleavage method. Diagnos Mol Path 1996; 5:265–270.
51. Goi K, Takagi M, Iwata S, et al. DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation. Cancer Res 1997; 57:1895–1902.
52. Grayson GH, Moore S, Schneider BG, et al. Novel germline mutation of the p53 tumor suppressor gene in a child with incidentally discovered adrenal cortical carcinoma. Am J Pediatr Hematol Oncol 1994; 16:341–347.
53. Güran S, Tunca Y, Imirzalioğlu N. Hereditary TP53 codon 292 and somatic P16 INK4A codon 94 mutations in a Li–Fraumeni syndrome family. Cancer Genet Cytogenet 1999; 113:145–151.
54. Gutierrez M.I, Bhatia KG, Barreiro C, et al. A de novo p53 germline mutation affecting codon 151 in a six year old child with multiple tumors. Hum Mol Genet 1994; 3:2247–2248.
55. Hamelin R, Barichard F, Henry I, et al. Single base pair germline deletion in the p53 gene in a cancer predisposed family. Hum Genet 1994; 94:88–90.
56. Horio Y, Suzuki H, Ueda R, et al. Predominantly tumor-limited expression of a mutant allele in a Japanese family carrying a germline p53 mutation. Oncogene 1994; 9:1231–1235.
57. Hung J, Mims B, Lozano G, et al. TP53 mutation and haplotype analysis of two large african american families. Hum Mutat 1999; 14:216–221.
58. Huusko P, Castén, K, Launonen V, et al. Germ-line TP53 mutations in Finnish cancer families exhibiting features of the Li–Fraumeni syndrome and negative for BRCA1 and BRCA2. Cancer Genet Cytogenet 1999; 112:9–14.
59. Iavarone A, Matthay KK, Steinkirchner TM, et al. Germ-line and somatic p53 gene mutations in multifocal osteogenic sarcoma. Proc Natl Acad 1992; 89:4207–4209.
60. Jolly KW, Malkin D, Douglass EC, et al. Splice-site mutation of the p53 gene in a family with hereditary breast–ovarian cancer. Oncogene 1994; 9:97–102.
61. Kovar H, Auinger A, Jug G, et al. p53 mosaicism with an exon 8 germline mutation in the founder of a cancer-prone pedigree. Oncogene 1992; 7:2169–2173.
62. Kupryjnćzyk J, Thor AD, Beauchamp R, et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993; 90:4961–4965.
63. Kyritsis AP, Bondy ML, Xiao M, et al. Germline p53 gene mutations in subsets of glioma patients. J Natl Cancer Inst 1994; 86:344–349.
64. Law JC, Strong LC, Chidambaram A, et al. A germ line mutation in exon 5 of the p53 gene in an extended cancer family. Cancer Res 1991; 51:6385–6387.
65. Li Y-J, Sanson M, Hoang-Xuan K, et al. Incidence of germ-line p53 mutations in patients with gliomas. Int J Cancer Pred Oncol 1995; 64:383–387.
66. Lomax ME, Barnes DM, Gilchrist R, et al. Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li–Fraumeni like family. Oncogene 1997; 14:1869–1874.
67. Lübbe J, von Ammon K, Watanabe K, et al. Familial brain tumour sydrome associated with a p53 germline deletion of codon 236. Brain Path 1995; 5:15–23.
68. Luca JW, Strong LC, Hansen MF. A germline missense mutation R337C in exon 10 of the human p53 gene. Hum Mutat 1998; (Suppl. 1):S58–S61.
69. MacGeoch C, Turner G, Bobrow LG, et al. Heterogeneity in Li–Fraumeni families: p53 mutation analysis and immunohistochemical staining. J Med Genet 1995; 32:186–190.
70. Malkin D, Friend SH, Li FP, et al. Germ-line mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 1997; 336:734.
71. Malkin D, Jolly KW, Barbier N, et al. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 1992; 326:1309–1315.
72. Mazoyer S, Lalle P, Moyret-Lalle, et al. Two germ-line mutations affecting the same nucleotide at codon 257 of p53 gene, a rare site for mutations. Oncogene 1994; 9:1237–1239.
73. McIntyre JF, Smith-Sorensen B, Friend SH, et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol 1994; 12:925–930.
74. Metzger AK, Sheffield VC, Duyk G, et al. Identification of a germline mutation in the p53 gene in a patient with an intracranial ependymoma. Proc Natl Acad Sci USA 1991; 88:7825–7829.
75. Moutou C, Le Bihan C, Chompret A, et al. Genetic transmission of susceptibility to cancer in families of children with soft tissue sarcomas. Cancer 1996; 78:1483–1491.
76. Murakawa Y, Yokoyama A, Kato S, et al. Astrocytoma and B-cell lymphoma development in a man with a p53 germline mutation. Jpn J Clin Oncol 1998; 28:631–637.
77. Nadav Y, Partorino U, Nicholson AG. Multiple synchronous lung cancers and atypical adenomatous hyperplasia in Li–Fraumeni syndrome. Histopathology 1998; 33:52–54.
78. Orellana C, Martinez F, Hernandez-Marti M, et al. A novel TP53 germ-line mutation identified in a girl with a primitive neuroectodermal tumor and her father. Cancer Genet Cytogenet 1998; 105:103–108.
79. Panizo C, Patĩno A, Calasanz J, et al. Emergence of secondary acute leukemia in a patient treated for osteosarcoma: implications of germline TP53 mutations. Med Pediatr Oncol 1998; 30:165–169.
80. Pivnick EK, Furman WL, Velagaleti GVN, et al. Simultaneous adrenocortical carcinoma and ganglioneuroblastoma in a child with Turner syndrome and germline p53 mutation. J Med Genet 1998; 35:328–332.
81. Plummer SJ, Santiáñez-Koref M, Kurosaki T, et al. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li–Fraumeni syndrome family. Oncogene 1994; 9:3273–3280.
82. Ponten F, Berg C, Ahmadian A, et al. Molecular pathology in basal cell cancer with p53 as a genetic marker. Oncogene 1997; 15:1059–1067.
83. Porter DE, Holden ST, Steel CM, et al. A significant proportion of patients with osteosarcoma may belong to Li–Fraumeni cancer families. J Bone Joint Surg 1992; 74-B:883–886.
84. Pratt CB, Meyer WH, Luo X, et al. Second malignant neoplasms occurring in survivors of osteosarcoma. Cancer 1997; 80:960–965.
85. Prosser J, Porter D, Coles C, et al. Constitutional p53 mutation in a non-Li–Fraumeni cancer family. Br J Cancer 1992; 65:527–528.
86. Quesnel S, Verselis S, Portwine C, et al. p53 compound heterozygosity in a severely affected child with Li–Fraumeni syndrome. Oncogene 1999; 18:3970–3978.
87. Rapakko K, Allinen M, Syrjakoski K, et al. Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites. Br J Cancer 2001; 84:116–119.
88. Reifenberger J, Janssen G, Weber R, et al. Primitive neuroectodermal tumors of the cerebral hemispheres in two siblings with TP53 germline mutation. J Neuropathol Exp Neurol 1998; 57:179–187.
89. Rines RD, van Orsouw NJ, Sigalas I, et al. Comprehensive mutational scanning of the p53 coding region by two-dimensional gene scanning. Carcinogenesis 1998; 19:979–984.
90. Russo CL, McIntyre J, Goorin AM, et al. Secondary breast cancer in patients presenting with osteosarcoma: possible involvement of germline p53 mutations. Med Paediatr Oncol 1994; 23:354–358.
91. Saeki Y, Tamura K, Yamamoto Y, et al. Germline p53 mutation at codon 133 in a cancer-prone family. J Mol Med 1997; 75:50–56.
92. Sameshima Y, Tsunematsu Y, Watanabe S, et al. Detection of novel germ-line p53 mutations in diverse-cancer-prone families identified by selecting patients with childhood adrenocortical carcinoma. J Natl Cancer Inst 1992; 84:703–707.
93. Scott RJ, Krummenacher F, Mary JL, et al. Vererbbare p53-Mutation bei einem Patienten mit Mehrfachtumoren: Bedeutung für die genetische Beratung. Schweiz Med Wochenschr 1993; 123:1287–1292.
94. Sedlacek Z, Kodet R, Kriz V, et al. Two Li–Fraumeni syndrome families with novel germline p53 mutations: loss of the wild-type p53 allele in only 50 per cent of tumours. Br J Cancer 1998; 77:1034–1039.
95. Sedlacek Z, Kriz V, Seemanova E, et al. Methodological detection of germinal mutations in the tumour suppressing gene p53. Casopis Lekaru Ceskych 1996; 135:762–767.
96. Shay JW, Tomlinson G, Piatyszek MA, Gollahon LS. Spontaneous in vitro immortalization of breast epithelial cells from a patient with Li–Fraumeni syndrome. Mol Cell Biol 1995; 15:425–432.
97. Shibata A, Tsai YC, Press MF, et al. Clonal analysis of bilateral breast cancer. Clin Cancer Res 1996; 2:743–748.
98. Shiseki M, Nishikawa R, Yamamoto H, et al. Germ-line p53 mutation is uncommon in patients with triple primary cancers. Cancer Lett 1993; 73:51–57.
99. Sidransky D, Tokino T, Helzlsouer K, et al. Inherited p53 gene mutations in breast cancer. Cancer Res 1992; 52:2984–2986.
100. Speiser P, Gharehbaghi-Schnell E, Eder S, et al. A constitutional de novo mutation in exon 8 of the p53 gene in a patient with multiple primary malignancies. Br J Cancer 1996; 74:269–273.
101. Stolzenberg M-C, Brugéres L, Gardes M, et al. Germ-line exclusion of a single p53 allele by premature termination of translation in a Li–Fraumeni syndrome family. Oncogene 1994; 9:2799–2804.
102. Strauss EA, Hosler MR, Herzog P, et al. Complex replication error causes p53 mutation in a Li–Fraumeni family. Cancer Res 1995; 55:3237–3241.
103. Sugano K, Taniguchi T, Saeki M, et al. Germline p53 mutation in a case of Li–Fraumeni syndrome presenting gastric cancer. Jpn J Clin Oncol 1999; 29:513–516.
104. ARF and CDK4 alterations in familial glioma. Am J Med Genet 2000; 92:136–141.
105. Toguchida J, Yamaguchi T, Dayton SH, et al. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 1992; 326:1301–1308.
106. Vahteristo P, Tamminen A, Karvinen P, et al. p53, CHK2, and CHK1 Genes in Finnish families with Li–Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res 2001; 61:5718–5722.
107. Varley JM, Attwooll C, White G, et al. Characterization of germline TP53 splicing mutations and their genetic and functional analysis. Oncogene 2001; 20:2647–2654.
108. Varley JM, McGown G, Thorncroft M, et al. A previously undescribed mutation within the tetramerisation domain of TP53 in a family with Li–Fraumeni syndrome. Oncogene 1996; 12:2437–2442.
109. Varley JM, McGown G, Thorncroft M, et al. Are there lowpenetrance tp53 alleles? Evidence from childhood adrenocortical tumors. Am J Hum Genet 1999; 65:995–1006.
110. Ribeiro RC, Sandrini F, Figueiredo B, et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA 2001; 98:9330–9335.
111. Latronico AC, Pinto EM, Domenice S, et al. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab 2001; 86:4970–4973.
112. Varley JM, McGown G, Thorncroft M, et al. Germ-line mutations of TP53 in Li–Fraumeni families: an extended study of 39 families. Cancer Res 1997; 57:3245–3252.
113. Varley JM, Thorncroft M, McGown G, et al. A novel deletion within exon 6 of TP53 in a family with Li Fraumeni-like syndrome, and LOH in a benign lesion from a mutation carrier. Cancer Genet Cytogenet 1996; 90:14–16.
114. Verselis S, Rheinwald JG, Fraumeni JF, et al. Novel p53 splice site mutations in three families with Li–Fraumeni syndrome. Oncogene 2000; 19:4230–4235.
115. Vital A, Bringuier P-P, Huang H, et al. Astrocytomas and choroid plexus tumors in two families with identical p53 germline mutations. J Neuropathol Exp Neurol 1998; 57:1061–1069.
116. Wagner J, Portwine C, Rabin K, et al. High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst 1994; 86:1707–1710.
117. Warneford SG, Witton LJ, Townsend ML, et al. Germ-line splicing mutation of the p53 gene in a cancer-prone family. Cell Growth Different 1992; 3:839–846.
118. Wilkin F, Gagne N, Paquette J, et al. Pediatric adrenocortical tumors: molecular events leading to insulin-like growth factor II gene overexpression. J Clin Endocrinol Metab 2000; 85:2048–2056.
119. Yonemoto T, Tatezaki S-I, Ishii T, et al. Two cases of osteosarcoma occurring as second malignancy of childhood cancer. Anticancer Res 1999; 19:5563–5566.
120. Zhou X-P, Sanson M, Hoang-Xuan K, et al. Germline mutations of p53 but not p16/cdkn2 or pten/mmac1 tumor suppressor genes predispose to gliomas. Ann Neurol 1999; 46:913–916.
121. Olivier M, Eeles R, Hollstein M, et al. The IARC database: new online mutation analysis and recommendations to users. Hum Mutat 2002; 19:607–614.
122. Sun X-F, Johannsson O, Hakansson S, et al. A novel p53 germline alteration identified in a late onset breast cancer kindred. Oncogene 1996; 13:407–411.
123. Avigad S, Barel D, Blau O, et al. A novel germ line p53 mutation in intron 6 in diverse childhood malignancies. Oncogene 1997; 14:1541–1545.
124. Barel D, Avigad S, Mor C, et al. A novel germ-line mutation in the noncoding region of the p53 gene in a Li–Fraumeni family. Cancer Genet Cytogenet 1998; 103:1–6.
125. Lehman TA, Haffty BG, Carbone CJ, et al. Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer. Cancer Res 2000; 60:1062–1069.
126. Ishioka C, Frebourg T, Yan Y, et al. Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nature Genet 1993; 5:124–129.
127. Birch JM, Blair V, Kelsey AM, et al. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li–Fraumeni syndrome. Oncogene 1998; 17:1061–1068.
128. Rapakko K, Allinen M, Syrjakoski K, et al. Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites. Br J Cancer 2001; 84:116–119.
129. Zelada-Hedman M, Børresen-Dale A-L, Claro A, et al. Screening for TP53 mutations in patients and tumours from 109 Swedish breast cancer families. Br J Cancer 1997; 75:1201–1204.
130. May P, May E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 1999; 18:7621–7636.
131. Hollstein M, Hergenhahn M, Yang Q, et al. New approaches to understanding p53 gene tumor mutation spectra. Mutat Res 1999; 431:199–209.
132. Varley JM, Evans DGR, Birch JM. Li–Fraumeni syndrome–a molecular and clinical review. Br J Cancer 1997; 76:1–14.
133. Cho Y, Gorina S, Jeffrey PD, et al. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994; 265:346–355.
134. Lane DP. p53, guardian of the genome. Nature 1992; 358:15–16.
135. Frebourg T, Kassel J, Lam KT, et al. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. Proc Natl Acad Sci USA 1992; 89:6413–6417.
136. Milner J, Medcalf EA. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 1991; 65:765–774.
137. DiGiammarino EL, Lee AS, Cadwell C, et al. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nature Struct Biol 2002; 9:12–16.
138. Dittmer D, Pati S, Zambetti G, et al. Gain of function mutations in p53. Nature Genet 1993; 4:42–46.
139. Chen J-Y, Funk WD, Wright WE, et al. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene 1993; 8:2159–2166.
140. Kawamura M, Yamashita T, Segawa K, et al. The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity. Oncogene 1996; 12:2361–2367.
141. Varley JM, Thorncroft M, McGown G, et al. A detailed loss of heterozygosity on chromosome 17 in tumours from Li–Fraumeni patients carrying a mutation to the TP53 gene. Oncogene 1997; 14:865–871.
142. Kleihues P, Schäuble B, Hausen, A, et al. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 1997; 150:1–13.
143. Nichols KE, Malkin D, Garber JE, et al. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Bio Prev 2001; 10:83–87.
144. Birch JM, Alston RD, McNally RJQ, et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 2001; 20:4621–4628.
145. Le Bihan C, Moutou C, Brugiéres L, et al. ARCAD: a method for estimating age-dependent disease risk associated with mutation carrier status from family data. Genet Epidemiol 1995; 12:13–25.
146. Trkova M, Hladikova M, Kasal P, et al. Is there anticipation in the age at onset of cancer in families with Li–Fraumeni syndrome? J Hum Genet 2002; 47:381–386.
147. Marutani M, Tonoki H, Tada M, et al. Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme. Cancer Res 1999; 59:4765–4769.
148. Birch JM, Heighway J, Teare MD, et al. Linkage studies in a Li–Fraumeni family with increased expression of p53 protein but no germline mutation in p53. Br J Cancer 1994; 70:1176–1181.
149. Evans SC, Mims B, McMasters KM, et al. Exclusion of a p53 germline mutation in a classic Li–Fraumeni syndrome family. Hum Genet 1998; 102:681–686.
150. Burt EC, McGown G, Thorncroft M, et al. Exclusion of the genes CDKN2 and PTEN as causative gene defects in Li–Fraumeni syndrome. Br J Cancer 1999; 80:9–10.
151. Bell DW, Varley JM, Szydlo TE, et al. Heterozygous germ line hCHK2 mutations in Li–Fraumeni syndrome. Science 1999; 286:2528–2531.
152. The CHEK2-Breast Cancer Consortium. Low penetrance susceptibility to breast cancer due to CHEK2*1100del C in noncarriers of BRCA1 or BRCA2 mutations. Nature Genet 2002; 31:55–59.
153. Sodha N, Houlston RS, Bullock S, et al. Increasing evidence that germline mutations in CHEK2 do not cause Li–Fraumeni syndrome. Human Mutat 2002; 20: 460–462.
154. Bougeard G, Charbonnier F, Moerman A, et al. Early-onset brain tumor and lymphoma in MSH2-deficient children. Am J Hum Genet 2003; 72:213–216.
155. Evans DGR, Birch JM, Thorncroft M, et al. Low rate of TP53 germline mutations in breast/sarcoma families not fulfilling classical criteria for Li–Fraumeni syndrome. J Med Genet 2002; 39:941–944.